Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445385 | 0.86 | PGR (0.40) | GRM2NR4A2 | |
| SCHEMBL4474719 | 0.84 | PDE3B (0.39) | PDE3BPDE3A | |
| SCHEMBL4445299 | 0.83 | ALDH1A1 (0.39) | MDM2 | |
| SCHEMBL4460630 | 0.83 | GRM2 (0.41) | GRM2 | |
| SCHEMBL4463022 | 0.82 | MDM2 (0.39) | PDE3BPDE3ASCN9AMDM2 | |
| SCHEMBL4458127 | 0.82 | GRM2 (0.38) | GRM2PDE3BPDE3A | |
| SCHEMBL4454827 | 0.81 | ESR2 (0.39) | PDE3BPDE3A | |
| SCHEMBL4447352 | 0.80 | GRM2 (0.37) | GRM2MDM2 | |
| SCHEMBL4469790 | 0.79 | PTGDR2 (0.35) | GRM2PDE3BPDE3APTGDR2 | |
| SCHEMBL4449987 | 0.77 | HCRTR1 (0.39) | HCRTR1HCRTR2PDE3BPDE3ACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885HCRTR1 3435/4885HCRTR2 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.